Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.
NextCure, Inc. has presented new preclinical data at the Brittle Bone Society Meeting showing that its novel anti-Siglec-15 antibody, NC605, significantly improves bone microarchitecture and reduces ...
A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...
The global Phase 3 Cosmic study evaluated the effect of setrusumab on reduction in annualized fracture rate in patients aged 2 to <7 years compared to bisphosphonates. The Cosmic study has enrolled 69 ...
Osteogenesis imperfecta (OI) is the most common genetic form of brittle bone disease and results in defects of both bone and connective tissue. OI patients can have significant problems with mobility ...
Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to ...
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and ...
Zacks Investment Research on MSN
Rare, MREO tank as osteogenesis study fails to meet primary endpoint
Shares of Ultragenyx Pharmaceutical RARE and Mereo BioPharma MREO plunged 42.3% and 87.6%, respectively, on Dec. 29 after the ...
Researchers have successfully regenerated damaged skull bones in mice by creating a freestanding, biomimetic scaffold that combines a piezoelectric framework and the growth-promoting properties of a ...
Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback